Artwork

Content provided by Erin Harris. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Erin Harris or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!

Breaking Down Solid Tumors with Triumvira Immunologics' Dr. Paul Lammers

21:33
 
Share
 

Manage episode 396048366 series 2945689
Content provided by Erin Harris. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Erin Harris or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

We love to hear from our listeners. Send us a message.

Paul Lammers, M.D., M.Sc., CEO of Triumvira Immunologics joins Cell & Gene: The Podcast to talk to Host Erin Harris about TAC, the company's proprietary T cell Antigen Coupler, which has both autologous and allogeneic approaches. They also discuss targeting relapsed or refractory HER2-positive solid tumors and CLDN18.2-positive solid tumors. And they cover a realistic outlook on the evolution of cancer treatment.

  continue reading

85 episodes

Artwork
iconShare
 
Manage episode 396048366 series 2945689
Content provided by Erin Harris. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Erin Harris or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

We love to hear from our listeners. Send us a message.

Paul Lammers, M.D., M.Sc., CEO of Triumvira Immunologics joins Cell & Gene: The Podcast to talk to Host Erin Harris about TAC, the company's proprietary T cell Antigen Coupler, which has both autologous and allogeneic approaches. They also discuss targeting relapsed or refractory HER2-positive solid tumors and CLDN18.2-positive solid tumors. And they cover a realistic outlook on the evolution of cancer treatment.

  continue reading

85 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Quick Reference Guide